319 related articles for article (PubMed ID: 35743191)
1. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.
Michelotti A; de Scordilli M; Bertoli E; De Carlo E; Del Conte A; Bearz A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743191
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
3. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
4. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
6. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
Song Z; Su H; Zhang Y
Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
[TBL] [Abstract][Full Text] [Related]
7. Path Less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer.
Lim SM; Lee JB; Oya Y; Nutzinger J; Soo R
JCO Oncol Pract; 2024 Jan; 20(1):47-56. PubMed ID: 37733983
[TBL] [Abstract][Full Text] [Related]
8. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
10. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876
[TBL] [Abstract][Full Text] [Related]
11. Molecular Targets Beyond the Big 3.
Reckamp KL
Thorac Surg Clin; 2020 May; 30(2):157-164. PubMed ID: 32327174
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer.
Grant MJ; Woodard GA; Goldberg SB
Hematol Oncol Clin North Am; 2023 Jun; 37(3):513-531. PubMed ID: 37024389
[TBL] [Abstract][Full Text] [Related]
13. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
14. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
15. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
16. Targeting molecular alterations in non-small-cell lung cancer: what's next?
López-Castro R; García-Peña T; Mielgo-Rubio X; Riudavets M; Teixidó C; Vilariño N; Couñago F; Mezquita L
Per Med; 2022 Jul; 19(4):341-359. PubMed ID: 35748237
[TBL] [Abstract][Full Text] [Related]
17. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
[TBL] [Abstract][Full Text] [Related]
18. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
19. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Halliday PR; Blakely CM; Bivona TG
Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Tan AC; Tan DSW
J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
